Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure

Summary from the Second International Conference on Pediatric Cardiomyopathy

Paul F. Kantor, Paolo Rusconi, Steven E Lipshultz, Seema Mital, James D. Wilkinson, Michael Burch

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Biomarkers have established an important role in the diagnosis and prognosis of heart failure in adults, with early indications being that their sensitivity and specificity will be similar in the pediatric population. Since early detection of remodeling is vital to preemptive management in cardiomyopathy and in heart disease arising from congenital lesions, biomarkers may offer a means of identifying high risk patients before they develop symptoms. Although in current use, natriuretic peptides high sensitivity troponins, and C-reactive protein need to have their applications more clearly defined in pediatrics, by evidence based guidelines. Exploratory work should meanwhile continue to define the risk of disease progression in patients with dilated cardiomyopathy, and of sudden death in hypertrophic cardiomyopathy based on biomarker profiles. Further research into the interaction of the genetic basis of disease and proteomic biomarkers will be a valuable means of assessing the importance of different pathways of disease related ventricular remodeling.

Original languageEnglish
Pages (from-to)11-14
Number of pages4
JournalProgress in Pediatric Cardiology
Volume32
Issue number1
DOIs
StatePublished - Aug 1 2011

Fingerprint

Cardiomyopathies
Heart Failure
Biomarkers
Pediatrics
Troponin C
Natriuretic Peptides
Inborn Genetic Diseases
Ventricular Remodeling
Hypertrophic Cardiomyopathy
Dilated Cardiomyopathy
Sudden Death
C-Reactive Protein
Proteomics
Disease Progression
Heart Diseases
Guidelines
Sensitivity and Specificity
Research
Population

Keywords

  • Biological markers
  • Cardiomyopathy
  • Heart failure
  • Pediatric
  • Ventricular remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure : Summary from the Second International Conference on Pediatric Cardiomyopathy. / Kantor, Paul F.; Rusconi, Paolo; Lipshultz, Steven E; Mital, Seema; Wilkinson, James D.; Burch, Michael.

In: Progress in Pediatric Cardiology, Vol. 32, No. 1, 01.08.2011, p. 11-14.

Research output: Contribution to journalArticle

@article{ffa9aad4ebb74375a16d841de34b814d,
title = "Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: Summary from the Second International Conference on Pediatric Cardiomyopathy",
abstract = "Biomarkers have established an important role in the diagnosis and prognosis of heart failure in adults, with early indications being that their sensitivity and specificity will be similar in the pediatric population. Since early detection of remodeling is vital to preemptive management in cardiomyopathy and in heart disease arising from congenital lesions, biomarkers may offer a means of identifying high risk patients before they develop symptoms. Although in current use, natriuretic peptides high sensitivity troponins, and C-reactive protein need to have their applications more clearly defined in pediatrics, by evidence based guidelines. Exploratory work should meanwhile continue to define the risk of disease progression in patients with dilated cardiomyopathy, and of sudden death in hypertrophic cardiomyopathy based on biomarker profiles. Further research into the interaction of the genetic basis of disease and proteomic biomarkers will be a valuable means of assessing the importance of different pathways of disease related ventricular remodeling.",
keywords = "Biological markers, Cardiomyopathy, Heart failure, Pediatric, Ventricular remodeling",
author = "Kantor, {Paul F.} and Paolo Rusconi and Lipshultz, {Steven E} and Seema Mital and Wilkinson, {James D.} and Michael Burch",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.ppedcard.2011.06.003",
language = "English",
volume = "32",
pages = "11--14",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure

T2 - Summary from the Second International Conference on Pediatric Cardiomyopathy

AU - Kantor, Paul F.

AU - Rusconi, Paolo

AU - Lipshultz, Steven E

AU - Mital, Seema

AU - Wilkinson, James D.

AU - Burch, Michael

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Biomarkers have established an important role in the diagnosis and prognosis of heart failure in adults, with early indications being that their sensitivity and specificity will be similar in the pediatric population. Since early detection of remodeling is vital to preemptive management in cardiomyopathy and in heart disease arising from congenital lesions, biomarkers may offer a means of identifying high risk patients before they develop symptoms. Although in current use, natriuretic peptides high sensitivity troponins, and C-reactive protein need to have their applications more clearly defined in pediatrics, by evidence based guidelines. Exploratory work should meanwhile continue to define the risk of disease progression in patients with dilated cardiomyopathy, and of sudden death in hypertrophic cardiomyopathy based on biomarker profiles. Further research into the interaction of the genetic basis of disease and proteomic biomarkers will be a valuable means of assessing the importance of different pathways of disease related ventricular remodeling.

AB - Biomarkers have established an important role in the diagnosis and prognosis of heart failure in adults, with early indications being that their sensitivity and specificity will be similar in the pediatric population. Since early detection of remodeling is vital to preemptive management in cardiomyopathy and in heart disease arising from congenital lesions, biomarkers may offer a means of identifying high risk patients before they develop symptoms. Although in current use, natriuretic peptides high sensitivity troponins, and C-reactive protein need to have their applications more clearly defined in pediatrics, by evidence based guidelines. Exploratory work should meanwhile continue to define the risk of disease progression in patients with dilated cardiomyopathy, and of sudden death in hypertrophic cardiomyopathy based on biomarker profiles. Further research into the interaction of the genetic basis of disease and proteomic biomarkers will be a valuable means of assessing the importance of different pathways of disease related ventricular remodeling.

KW - Biological markers

KW - Cardiomyopathy

KW - Heart failure

KW - Pediatric

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=79961165951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961165951&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2011.06.003

DO - 10.1016/j.ppedcard.2011.06.003

M3 - Article

VL - 32

SP - 11

EP - 14

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1

ER -